A Phase 1 interventional study of AZD5363 and AZD5363 in Advanced Solid Malignancy,, Safety and Tolerability, and Pharmacokinetics, Pharmacodynamics,, sponsored by AstraZeneca. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2016-05-25.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability
This study is designed to investigate the safety, tolerability and pharmacokinetics of a new drug, AZD5363, in patients with advanced cancer . This study will investigate how the body handles AZD5363 (ie, how quickly the body absorbs and removes the drug), the comparison of a capsule and a tablet formulation and the effect of food on AZD5363 tablet formulation.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: -
Exclusion Criteria: -
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AZD5363 tablet twice daily followed by AZD5363 capsule twice daily on an intermittent regimen (4 days on, 3 days off).
Drug: AZD5363
AZD5363 tablet twice daily on an intermittent regimen (4 days on, 3 days off) with/without food on one occasion
Drug: AZD5363
Ratio of Css,Max for Day 4 to Day 11
The actual sampling times were used in the pharmacokinetics (PK) parameter calculations and PK parameters were derived using standard non-compartmental methods. Following the twice daily dosing in Cycle 1 at Day 4 and 11 for both the formulation switch and food effect investigations, the following PK parameters have been determined: Maximum plasma concentration at steady state (Css max), time to Css,max (tss max), minimum plasma concentration at steady state (Css min), area under the plasma concentration-time curve from zero to the end of the dosing interval (AUCss) and apparent clearance (CLss/F). Css max, tss max were determined by inspection of the concentration-time profiles. AUCss was calculated using the linear up / log down trapezoidal rule. CLss/F was determined from the ratio of dose/AUCss. Ratio of Css,max for Day 4 to Day 11 have been derived.
Time frame: Day 4 and Day 11
Ratio of AUCss for Day 4 to Day 11
The actual sampling times were used in the parameter calculations and PK parameters were derived using standard non-compartmental methods. Following the twice daily dosing in Cycle 1 at Day 4 and 11 for both the formulation switch and food effect investigations, the following PK parameters have been determined: Css max, tss max, Css min, area under the plasma concentration-time curve from zero to the end of the dosing interval (AUCss) and CLss/F. Css max, tss max were determined by inspection of the concentration-time profiles. AUCss was calculated using the linear up / log down trapezoidal rule. CLss/F was determined from the ratio of dose/AUCss. Ratio of AUCss for Day 4 to Day 11 have been derived.
Time frame: Day 4 and Day 11
Efficacy: Best Objective Response (BOR)
Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 guidelines for measurable, non-measurable, target lesions (TLs) and non-target lesions (NTLs) and the objective tumour response criteria was used. Categorisation of objective tumour response assessment was based on the RECIST 1.1 guidelines for response: CR (complete response, efined as disappearance of all target lesions), PR (partial response, defined as \>=30% decrease in the sum of the longest diameter of target lesions), SD (stable disease, defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression) and PD (progression of disease, defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion). BOR was the best overall response observed across the study and up to 36 weeks. Number of subjects with response (CR or PR) is described.
Time frame: Assessed every 6 weeks, up to 36 weeks
Efficacy: Disease Control at Week 12
Disease control = confirmed complete response + confirmed partial response + stable disease at 12 weeks
Time frame: Week 12
Efficacy: Target Lesion Size, Percentage Change From Baseline at Week 12
Tumour size is the sum of the longest diameters of the target lesions. Target lesions are measurable tumour lesions. The percentage change in target lesion tumour size at each week 12 for which data are available was obtained for each subject taking the difference between the sum of the target lesion at each week 12 and the sum of the target lesions at baseline divided by the sum of the target lesions at baseline multiplied by 100 (i.e. (week 12) - baseline)/baseline \* 100).
Time frame: Week 12
Efficacy: Target Lesion Size, Best Percentage Change From Baseline
Tumour size is the sum of the longest diameters of the target lesions. Target lesions are measurable tumour lesions. best percentage change in tumour size from baseline is the maximum reduction from baseline or the minimum increase from baseline in the absence of a reduction from baseline based on all post baseline assessments.
Time frame: Assessed every 6 weeks up to 36 weeks
Efficacy: Progression-free Survival (PFS)
PFS is defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the subject withdraws from randomised therapy or receives another anti-cancer therapy prior to progression. Subjects who have not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions.
Time frame: Assessed every 6 weeks up to 36 weeks
There were 2 parts to this study: Part A (tablet formulation assessment) followed by Part B (food effect assessment). Part A: first patient enrolled on 18/12/2013 and last patient completed on 16/12/2014. Part B: first patient enrolled on 10/09/2014 and last patient completed on 22/07/2015. Part A was conducted at 3 sites and Part B at 2 sites.
| Milestone | Part A | Part B |
|---|---|---|
| Started | 18 | 12 |
| Completed | 18 | 12 |
| Not completed | 0 | 0 |
The actual sampling times were used in the pharmacokinetics (PK) parameter calculations and PK parameters were derived using standard non-compartmental methods. Following the twice daily dosing in Cycle 1 at Day 4 and 11 for both the formulation switch and food effect investigations, the following PK parameters have been determined: Maximum plasma concentration at steady state (Css max), time to Css,max (tss max), minimum plasma concentration at steady state (Css min), area under the plasma concentration-time curve from zero to the end of the dosing interval (AUCss) and apparent clearance (CLss/F). Css max, tss max were determined by inspection of the concentration-time profiles. AUCss was calculated using the linear up / log down trapezoidal rule. CLss/F was determined from the ratio of dose/AUCss. Ratio of Css,max for Day 4 to Day 11 have been derived.
| Ratio | Part A | Part B |
|---|---|---|
| Ratio of Css,Max for Day 4 to Day 11 | 1.02 (0.86 to 1.20) | 0.67 (0.55 to 0.82) |
The actual sampling times were used in the parameter calculations and PK parameters were derived using standard non-compartmental methods. Following the twice daily dosing in Cycle 1 at Day 4 and 11 for both the formulation switch and food effect investigations, the following PK parameters have been determined: Css max, tss max, Css min, area under the plasma concentration-time curve from zero to the end of the dosing interval (AUCss) and CLss/F. Css max, tss max were determined by inspection of the concentration-time profiles. AUCss was calculated using the linear up / log down trapezoidal rule. CLss/F was determined from the ratio of dose/AUCss. Ratio of AUCss for Day 4 to Day 11 have been derived.
| Ratio | Part A | Part B |
|---|---|---|
| Ratio of AUCss for Day 4 to Day 11 | 0.90 (0.77 to 1.06) | 0.89 (0.76 to 1.05) |
Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 guidelines for measurable, non-measurable, target lesions (TLs) and non-target lesions (NTLs) and the objective tumour response criteria was used. Categorisation of objective tumour response assessment was based on the RECIST 1.1 guidelines for response: CR (complete response, efined as disappearance of all target lesions), PR (partial response, defined as \>=30% decrease in the sum of the longest diameter of target lesions), SD (stable disease, defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression) and PD (progression of disease, defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion). BOR was the best overall response observed across the study and up to 36 weeks. Number of subjects with response (CR or PR) is described.
| Participants | Part A | Part B |
|---|---|---|
| Efficacy: Best Objective Response (BOR) | 0 | 0 |
Disease control = confirmed complete response + confirmed partial response + stable disease at 12 weeks
| Participants | Part A | Part B |
|---|---|---|
| Efficacy: Disease Control at Week 12 | 1 | 3 |
Tumour size is the sum of the longest diameters of the target lesions. Target lesions are measurable tumour lesions. The percentage change in target lesion tumour size at each week 12 for which data are available was obtained for each subject taking the difference between the sum of the target lesion at each week 12 and the sum of the target lesions at baseline divided by the sum of the target lesions at baseline multiplied by 100 (i.e. (week 12) - baseline)/baseline \* 100).
| Percentage change from baseline | Part A | Part B |
|---|---|---|
| Efficacy: Target Lesion Size, Percentage Change From Baseline at Week 12 | 8.1 ± 14.72 | -1.5 ± 6.49 |
Tumour size is the sum of the longest diameters of the target lesions. Target lesions are measurable tumour lesions. best percentage change in tumour size from baseline is the maximum reduction from baseline or the minimum increase from baseline in the absence of a reduction from baseline based on all post baseline assessments.
| Percentage change from baseline | Part A | Part B |
|---|---|---|
| Efficacy: Target Lesion Size, Best Percentage Change From Baseline | 10.5 ± 13.62 | 0.2 ± 9.92 |
PFS is defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the subject withdraws from randomised therapy or receives another anti-cancer therapy prior to progression. Subjects who have not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions.
| weeks | Part A | Part B |
|---|---|---|
| Efficacy: Progression-free Survival (PFS) | 6.1 ± 13.62 | 13.7 ± 9.92 |
Collected over Adverse events with an onset date on or after the date of first dose and up to and including 28 days following the date of last dose of study medication were collected.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A | — | 5/18 (27.8%) | 18/18 (100%) |
| Part B | — | 6/12 (50%) | 12/12 (100%) |
| Event | Part A | Part B |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/18 | 3/12 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 0/18 | 2/12 |
| Pneumonia mycoplasmalInfections and infestations | 0/18 | 1/12 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/18 | 1/12 |
| VomitingGastrointestinal disorders | 1/18 | 1/12 |
| StomatitisGastrointestinal disorders | 0/18 | 1/12 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/18 | 1/12 |
| Rash papularSkin and subcutaneous tissue disorders | 1/18 | 1/12 |
| PyrexiaGeneral disorders | 1/18 | 0/12 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/18 | 0/12 |
| Event | Part A | Part B |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 14/18 | 9/12 |
| FatigueGeneral disorders | 7/18 | 8/12 |
| NauseaGastrointestinal disorders | 8/18 | 8/12 |
| HyperglycaemiaMetabolism and nutrition disorders | 10/18 | 6/12 |
| Dry skinSkin and subcutaneous tissue disorders | 4/18 | 5/12 |
| VomitingGastrointestinal disorders | 5/18 | 5/12 |
| PyrexiaGeneral disorders | 2/18 | 3/12 |
| Respiratory tract infectionInfections and infestations | 0/18 | 3/12 |
| AnaemiaBlood and lymphatic system disorders | 4/18 | 2/12 |
| Decreased appetiteMetabolism and nutrition disorders | 4/18 | 2/12 |
| Age, Customized(Participants) | Part A | Part B | Total |
|---|---|---|---|
| <50 years | 4 | 1 | 5 |
| Between 50 and 65 years | 9 | 6 | 15 |
| >=65 years | 5 | 5 | 10 |
| Sex: Female, Male(Participants) | Part A | Part B | Total |
|---|---|---|---|
| Female | 8 | 7 | 15 |
| Male | 10 | 5 | 15 |
The record gives a start of Dec 2013, a primary completion of Feb 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Capivasertib